论文部分内容阅读
目的:通过强化药物治疗,观察稳定性心绞痛的药物治疗疗效。方法:选择我院心内科住院治疗的患者90例,随访患者1~24个月的心脏不良事件(心源性死亡、非致死性心肌梗死、因急性冠状动脉综合征入院、再次介入治疗、心力衰竭、心绞痛复发率)和生活质量积分。结果:本组患者SF-36评分出院时,身体健康(627.0±13.0)分,心理健康(555.0±12.0)分,总分为(1182.0±11.0)分;20个月时身体健康评(633.0±18.0)分,心理健康(579.0±11.0)分,总分为(1212.0±17.0)分。20个月时本组患者心血管事件发生25例,约占总数的30.0%。结论:稳定性心绞痛强化药物治疗作为最初的治疗方案,可被安全的广泛应用于绝大多数稳定性心绞痛的患者,但大约有三分之一的患者药物治疗后因要控制症状或因随后发展为急性冠脉综合征而需要进行再血管化治疗。
Objective: To observe the effect of drug treatment of stable angina pectoris through intensive drug treatment. Methods: Ninety hospitalized patients in our department of cardiology were followed up for 1 to 24 months. Cardiac adverse events (cardiogenic death, non-fatal myocardial infarction, admission to hospital due to acute coronary syndrome, interventional therapy again, cardiac function Failure, angina recurrence rate) and quality of life points. Results: At the time of discharge, the SF-36 scores of healthy subjects (627.0 ± 13.0), mental health (555.0 ± 12.0) and total score (1182.0 ± 11.0) 18.0) points, mental health (579.0 ± 11.0) points, the total score was (1212.0 ± 17.0) points. At 20 months, 25 patients had cardiovascular events, accounting for 30.0% of the total. Conclusions: As the initial treatment regimen, stable angina pectoris medications can be safely and widely used in the majority of patients with stable angina pectoris, but about one third of patients need to control their symptoms or subsequently develop Acute coronary syndromes require revascularization.